David Gibeon1, Liam G Heaney2, Chris E Brightling3, Rob Niven4, Adel H Mansur5, Rekha Chaudhuri6, Christine E Bucknall7, Andrew N Menzies-Gow8. 1. Royal Brompton Hospital, London, England; Airways Disease, National Heart and Lung Institute, Imperial College, London, England. 2. Centre for Infection and Immunity, Queen's University of Belfast, Belfast, Ireland. 3. University of Leicester, Leicester, England. 4. University of Manchester, Manchester, England; University Hospital of South Manchester, South Manchester, England. 5. Birmingham Heartlands Hospital, University of Birmingham, Birmingham, England. 6. Gartnavel General Hospital, University of Glasgow, Glasgow, Scotland. 7. Glasgow Royal Infirmary, Glasgow, Scotland. 8. Royal Brompton Hospital, London, England. Electronic address: A.Menzies-Gow@rbht.nhs.uk.
Abstract
BACKGROUND: Systematic assessment of severe asthma can be used to confirm the diagnosis, identify comorbidities, and address adherence to therapy. However, the prospective usefulness of this approach is yet to be established. The objective of this study was to determine whether the systematic assessment of severe asthma is associated with improved quality of life (QoL) and health-care use and, using prospective data collection, to compare relevant outcomes in patients referred with severe asthma to specialist centers across the United Kingdom. METHODS: Data from the National Registry for dedicated UK Difficult Asthma Services were used to compare patient demographics, disease characteristics, and health-care use between initial assessment and a median follow-up of 286 days. RESULTS: The study population consisted of 346 patients with severe asthma. At follow-up, there were significant reductions in health-care use in terms of primary care or ED visits (66.4% vs 87.8%, P < .0001) and hospital admissions (38% vs 48%, P = .0004). Although no difference was noted in terms of those requiring maintenance oral corticosteroids, there was a reduction in steroid dose (10 mg [8-20 mg] vs 15 mg [10-20 mg], P = .003), and fewer subjects required short-burst steroids (77.4% vs 90.8%, P = .01). Significant improvements were seen in QoL and control using the Asthma Quality of Life Questionnaire and the Asthma Control Questionnaire. CONCLUSIONS: To our knowledge, this is the first time that a prospective study has shown that a systematic assessment at a dedicated severe asthma center is associated with improved QoL and asthma control and a reduction in health-care use and oral steroid burden.
BACKGROUND: Systematic assessment of severe asthma can be used to confirm the diagnosis, identify comorbidities, and address adherence to therapy. However, the prospective usefulness of this approach is yet to be established. The objective of this study was to determine whether the systematic assessment of severe asthma is associated with improved quality of life (QoL) and health-care use and, using prospective data collection, to compare relevant outcomes in patients referred with severe asthma to specialist centers across the United Kingdom. METHODS: Data from the National Registry for dedicated UK Difficult Asthma Services were used to compare patient demographics, disease characteristics, and health-care use between initial assessment and a median follow-up of 286 days. RESULTS: The study population consisted of 346 patients with severe asthma. At follow-up, there were significant reductions in health-care use in terms of primary care or ED visits (66.4% vs 87.8%, P < .0001) and hospital admissions (38% vs 48%, P = .0004). Although no difference was noted in terms of those requiring maintenance oral corticosteroids, there was a reduction in steroid dose (10 mg [8-20 mg] vs 15 mg [10-20 mg], P = .003), and fewer subjects required short-burst steroids (77.4% vs 90.8%, P = .01). Significant improvements were seen in QoL and control using the Asthma Quality of Life Questionnaire and the Asthma Control Questionnaire. CONCLUSIONS: To our knowledge, this is the first time that a prospective study has shown that a systematic assessment at a dedicated severe asthma center is associated with improved QoL and asthma control and a reduction in health-care use and oral steroid burden.
Authors: Nicolas Kahn; Lowie E G W Vanfleteren; Georgios Kaltsakas; Vasileios Andrianopoulos; Daniela Gompelmann; Corina de Jong; Felix J F Herth Journal: J Thorac Dis Date: 2018-09 Impact factor: 2.895
Authors: Ricardo A Mosquera; Elenir B Caramel Avritscher; Aravind Yadav; Claudia Pedroza; Cheryl L Samuels; Tomika S Harris; Cecilia Tetzlaff; Julie Eapen; Traci R Gonzales; Charles Green; Jon E Tyson Journal: J Asthma Date: 2020-02-06 Impact factor: 2.515
Authors: John Blakey; Li Ping Chung; Vanessa M McDonald; Laurence Ruane; John Gornall; Chris Barton; Sinthia Bosnic-Anticevich; John Harrington; Mark Hew; Anne E Holland; Trudy Hopkins; Lata Jayaram; Helen Reddel; John W Upham; Peter G Gibson; Philip Bardin Journal: Respirology Date: 2021-09-29 Impact factor: 6.175
Authors: Rodrigo Athanazio; Regina Carvalho-Pinto; Frederico Leon Arrabal Fernandes; Samia Rached; Klaus Rabe; Alberto Cukier; Rafael Stelmach Journal: BMC Pulm Med Date: 2016-11-16 Impact factor: 3.317
Authors: Celeste Porsbjerg; Charlotte Ulrik; Tina Skjold; Vibeke Backer; Birger Laerum; Sverre Lehman; Crister Janson; Thomas Sandstrøm; Leif Bjermer; Barbro Dahlen; Bo Lundbäck; Dora Ludviksdottir; Unnur Björnsdóttir; Alan Altraja; Lauri Lehtimäki; Paula Kauppi; Jussi Karjalainen; Hannu Kankaanranta Journal: Eur Clin Respir J Date: 2018-03-06
Authors: Daniel P Henriksen; Uffe Bodtger; Kirsten Sidenius; Niels Maltbaek; Lars Pedersen; Hanne Madsen; Ehm A Andersson; Ole Norgaard; Louise Klokker Madsen; Bo L Chawes Journal: Eur Clin Respir J Date: 2018-11-07
Authors: Carlo Lombardi; Eleonora Savi; Maria Teresa Costantino; Enrico Heffler; Manlio Milanese; Giovanni Passalacqua; Giorgio Walter Canonica Journal: Clin Mol Allergy Date: 2016-04-19